Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Patrick Boisseau Elected Chairman of the ETPN

Published: Monday, March 25, 2013
Last Updated: Monday, March 25, 2013
Bookmark and Share
Program will focus on building a structure that speeds innovations’ time to market and patients, while keeping Europe’s nanomed IP at home.

CEA-Leti has announced that Patrick Boisseau, the head of Leti’s nanomedicine program, has been elected chairman of the European Technology Platform - Nanomedicine (ETPN), a joint initiative between industry, academia, clinicians and the European Commission to help build a profitable nanomedicine sector in Europe.

Nanomedicine development in Europe and globally has evolved from fundamental research in the first decade of this century to development of products, patents, clinical trials and regulatory approval.

Most of the innovation in Europe is occurring in research labs and small to midsize enterprises (SMEs), including start-ups that have spun off from universities and research institutes.

These SMEs typically conduct preclinical and early clinical proofs of concept with a goal of transferring the clinical development to large companies that have the financial resources and expertise to complete the costly and sometimes lengthy clinical trials and regulatory approval.

But optimism about nanomed’s potential impact on healthcare and for creating value and jobs has created intense global competition for nanomed IP and new technologies.

Boisseau said two of his primary goals during his two-year term as chairman of ETPN are keeping the nanomed innovation that is underway at many European facilities and SMEs in Europe and to help build a nanomedicine sector that can compete strongly with Asia and the U.S.

“One key way to do that is to organize a supply chain of SMEs to facilitate the transfer of innovation and technology to large companies and make these technologies available to patients as soon as possible,” he said.

Boisseau continued, “It also will require us to build key infrastructure in Europe, such as an EU nanotechnology characterization lab or a network of good manufacturing practices sites for medical nanomaterials. This initiative also will be a good opportunity for leading European institutes like KTH, EPFL, Helmholtz Fondation, Tecnalia, Fraunhofer, SINTEF and Leti to expand their nanomed partnerships with both SMEs and large companies.”

Boisseau has chaired the ETPN working group on nano diagnostics since the ETPN was formed in 2005.

“Nanomedicine, which is a key part of Leti’s focus on emerging healthcare technologies, holds tremendous potential to improve healthcare delivery for people all over the world,” said Leti CEO Laurent Malier.

Malier continued, “Leti’s focus on creating innovation in this field and transferring it to industry strongly supports the European Technology Platform - Nanomedicine’s mission, and Patrick Boisseau brings a practical and forward-looking perspective to his role as chairman of ETPN.”

In the same election, Dr. Laurent Levy, CEO of Nanobiotix, was elected vice chairman of ETPN. He represents SMEs on the platform’s executive board.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Leti and Diabeloop Project Aims at Developing Artificial Pancreas
Artificial pancreas will automatically deliver the appropriate dose of insulin to patients.
Saturday, July 25, 2015
Leti Announces Launch of First European Nanomedicine Characterization Laboratory
Project combines expertise of 9 partners in 8 countries to foster nanomedicine innovation and facilitate regulatory approval.
Tuesday, July 07, 2015
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!